Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

NMAD vs KPRX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

KPRX Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 8–2 Matrix Metrics)

KPRX Overall Winner 6-Pillar Tally: NMAD 0 – 4 KPRX (2 Tie) Matrix Metrics: NMAD 2 – 8 KPRX

As of Nov 20, 2026, Kiora Pharmaceuticals, Inc. (KPRX) is the stronger overall head-to-head candidate over NMAD (NMAD) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NMAD carries a Unified Composite Score of 47.9/100 (HOLD) at $2.56 (N/M Forward P/E, N/A operating margin), whereas KPRX carries 47.5/100 (HOLD) at $0.72 (1.7x Forward P/E, -890.2% operating margin).

  • Technical & Structure Timing Caution: NMAD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.1); meanwhile KPRX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 13.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NMAD vs KPRX
NMAD US Equity
NMAD
Institutional Equity
$2.56
+13.53% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.52β · 173% Vol
Unified Composite Score
47.9 / 100 HOLD
Tech 43.0 Fund 49.0 Flow 50.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.8%), weak momentum, RSI 38
RSI-14: 38.1 · SMA20: $3.37 · SMA50: $3.65
KPRX NASDAQ Head-to-Head Winner
Kiora Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$0.72
-12.28% 1D
Market Cap $3.6M
TTM Revenue $1.0M
Forward P/E 1.7x
Beta / 30D Vol 1.62β · 126% Vol
Unified Composite Score
47.5 / 100 HOLD
Tech 45.0 Fund 46.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.6%), weak momentum, RSI 14
RSI-14: 13.7 · SMA20: $1.46 · SMA50: $2.11

6-Pillar Scorecard Institutional Category Breakdown (NMAD 0 – 4 KPRX)

Columns: Metric · NMAD · KPRX
1. Valuation Multiples KPRX
Forward P/E N/M 1.7x
Trailing P/E N/M 1.7x
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale KPRX
Revenue Growth (YoY) N/A +0.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $1.0M
Market Cap N/A $3.6M
3. Profitability & Quality KPRX
Gross Margin N/A N/A
Operating Margin N/A -890.2%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -67.7%
4. Balance Sheet & Cash Flow KPRX
Cash Generation (TTM) N/A -$8.9M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $11M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NMAD (2) vs KPRX (8)
Institutional Metric NMAD KPRX Criterion Row Edge
Market Capitalization
Scale
N/A $3.6M Larger Scale KPRX
Trailing P/E Ratio
Valuation
N/M 1.7x Lower Multiple KPRX
Forward P/E Ratio
Valuation
N/M 1.7x Lower Multiple KPRX
Revenue Growth (YoY)
Growth
N/A +0.0% Higher Growth KPRX
Operating Margin (TTM)
Profitability
N/A -890.2% Higher Margin KPRX
Net Profit Margin
Profitability
N/A 0.0% Higher Margin KPRX
Return on Equity (ROE)
Capital Efficiency
N/A -67.7% Higher ROE KPRX
52-Week Range Position
Momentum
8% ($2–$8) 0% ($1–$3) Stronger Trend NMAD
Beta / 30D Volatility
Risk Regime
0.52β · 173% Vol 1.62β · 126% Vol Lower Realized Risk KPRX
Unified Institutional Score
Composite Signal
47.9 / 100 (HOLD) 47.5 / 100 (HOLD) Higher Composite NMAD
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.0M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$8.9M EBITDA ($11M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NMAD +40.07 pp
NMAD: -28.89% · KPRX: -68.96%
3M Horizon NMAD +35.5 pp
NMAD: -38.31% · KPRX: -73.81%
6M Horizon NMAD +6.64 pp
NMAD: -65.12% · KPRX: -71.76%
1Y Horizon NMAD +6.64 pp
NMAD: -65.12% · KPRX: -71.76%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NMAD vs KPRX. Trailing 12-month operating profitability (NMAD N/A vs KPRX -890.2%) and valuation multiples (NMAD N/M vs KPRX 1.7x Forward P/E) are benchmarked directly in Pillar 4 below.

NMAD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
KPRX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.0M
Gross MarginN/A
Op. Margin-890.2%
ROE / Fwd P/E-67.7% · 1.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NMAD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NMAD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
KPRX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KPRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NMAD Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
KPRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.6M market capitalization and -890.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NMAD vs KPRX Key Questions & Quantitative Answers

As of Nov 20, 2026, Kiora Pharmaceuticals, Inc. (KPRX) is the stronger overall head-to-head candidate over NMAD (NMAD) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NMAD carries a Unified Composite Score of 47.9/100 (HOLD) at $2.56 (N/M Forward P/E, N/A operating margin), whereas KPRX carries 47.5/100 (HOLD) at $0.72 (1.7x Forward P/E, -890.2% operating margin). Technical & Structure Timing Caution: NMAD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.1); meanwhile KPRX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 13.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

KPRX leads the Growth & Scale pillar: NMAD posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with KPRX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1.0M TTM revenue (N/A gross margin, -890.2% operating margin). On trailing 12-month operating scale, NMAD generates N/A in USD-normalized revenue versus $1.0M for KPRX. In operating R&D and SG&A reinvestment, NMAD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for KPRX.

KPRX screens cheaper on headline valuation multiples. NMAD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas KPRX trades at 1.7x Forward P/E, 1.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NMAD (N/A ROE) versus KPRX (-67.7% ROE) capital efficiency.

In options market volatility and institutional positioning, NMAD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.52β · 173% Vol realized risk). By comparison, KPRX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.62β · 126% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.